Francesco Schettini, MD PhD 🇮🇹🇪🇸🇪🇺
@FrancescoSche20
Followers
1K
Following
5K
Media
150
Statuses
1K
Medical Oncologist @hospitalclinic, Post-Doc Researcher @IDIBAPS, @EACRnews ambassador, @UniBarcelona #intrinsicsubtypes #biomarkerdevelopment #HER2low.
Barcellona, Spagna
Joined September 2019
Finally out in @ESMO_Open the main findings of my @myESMO #Fellowship research project focused on the.identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer. What did we find? A thread 🧵
2
21
85
RT @MichaelGnant: Important reading for all clinical trialists: always be aware of (and transparent about!) the event „classification“ for….
0
15
0
Today was a special one. For the first time, I served as a member of a PhD thesis committee. It was an incredibly meaningful experience, both my mother and father have done this for many years! (Hello Dad, I hope you could somehow see me from wherever you are now, and be proud).
0
1
17
RT @PTarantinoMD: One of my favorite posters of #ESMOBreast25, addressing an important question:. 👉What is the outcome of post-T-DXd treatm….
0
19
0
RT @matteolambe: Proffered paper session at #ESMOBreast25 with final results from #APHINITY trial at 11.3 years median follow-up addressing….
0
11
0
RT @stolaney1: Cristina Saura does an outstanding job discussing iza-bren, zani, and tucatinib +H. #ESMOBreast25 @myESMO @OncoAlert https:/….
0
20
0
RT @PTarantinoMD: Sara Tolaney from @DFCI_BreastOnc reviews a rainbow of novel treatment options becoming available for HR+/HER2- mBC over….
0
36
0
RT @_SOLTI: We wrap up a new edition of #ESMOBreast25 filled with science, connections, hard work, and EXCITEMENT!. From oral presentations….
0
6
0
RT @CejalvoM: Promising chemo-free option for HR+/HER2+ metastatic breast cancer: our phase 2a study shows zanidatamab + palbociclib + fulv….
0
16
0
Great time in Basel to address with @Roche physicians’ and patients’ needs to improve the collaboration on clinical trials. Thanks for inviting me!
0
0
6
RT @raffcolo: Additional proposed mechanisms to explain T-DXd efficacy… from preclinical studies. Out today on @NatureComms . https://t.c….
0
25
0
RT @ElisaAgostinett: Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠.Happy to sh….
thebreastonline.com
Leptomeningeal metastases (LM) in patients with breast cancer (BC) are associated with a dismal prognosis. We explored clinical characteristics and prognostic factors in patients with BC and LM in...
0
20
0
RT @tkoraysahin: 📢 Our comprehensive review on post-progression treatment strategies after CDK4/6 inhibitor in HR+/HER2− MBC is now publish….
0
44
0
RT @to_carla96: Te interesa la Oncología Médica? Ven el día 20 de marzo a las puertas abiertas del @hospitalclinic a conocer nuestro serv….
0
18
0
Si eres residente de #oncología al V año #R5 te interesa la investigación y te gusta o te gustaría prevalentemente enfocarte en cáncer de mama, @_SOLTI es tu lugar y #SOLTIYoung tu segunda casa. Podrás acceder a tutorías, becas y programas educativos por y para jóvenes. Súmate!.
💥#SOLTIYoung es un grupo creado por jóvenes y para jóvenes que ya cuenta con más de 80 miembros. Ahora, abrimos este espacio también a profesionales en su último año de formación. ➡️Si eres residente de oncología médica de 5º año con especial enfoque en cáncer de mama,
0
2
5
RT @PTarantinoMD: The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in….
0
169
0
RT @FilippoMontemu1: Looks interesting and worthy of a "slow resding"
pubmed.ncbi.nlm.nih.gov
Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undete...
0
2
0
RT @DFCI_BreastOnc: Check out this recently published paper on #CHEK2-related #BreastCancer and the real-world challenges associated with i….
0
16
0
RT @_SOLTI: 📍@MOliveira_MD : "Si todos los implicados en el abordaje del cáncer afrontamos estos retos en los próximos años, estaremos más….
0
2
0